TABLE 1.
Baseline characteristics according to diabetes status
| Total (N = 3295) | Patients without diabetes (N = 2117) | Patients with diabetes (N = 1178) | P‐value | ||
|---|---|---|---|---|---|
| Sex: male, n (%) | 1853 (56.2) | 1114 (52.6) | 739 (62.7) | <0.001 | |
| Age, median (IQR), years | 73.9 (62.0, 81.8) | 73.6 (59.9, 82.7) | 74.3 (64.9, 80.8) | 0.26 | |
| HbA1c, median (IQR), mmol/mol | 40 (36, 48) | 37 (34, 40) | 54 (47, 65) | <0.001 | |
| Blood glucose, median (IQR), mmol/L | 6.9 (5.9,8.8) | 6.3 (5.7, 7.4) | 9.3 (7.0, 12.1) | <0.001 | |
| Missing | 999 | 620 | 379 | ||
| C‐reactive protein, median (IQR), mg/L | 25 (4.3,72.0) | 21 (4, 66) | 30 (6.7, 86.0) | <0.001 | |
| Missing | 468 | 256 | 212 | ||
| Leukocytes, median (IQR), x 109/L | 6.8 (5.2,9.0) | 6.7 (5.0, 8.7) | 7.2 (5.5, 9.2) | <0.001 | |
| Missing | 340 | 159 | 181 | ||
| Comorbidities, n (%) | |||||
| Ischaemic heart disease | 759 (23.0) | 404 (19.1) | 355 (30.1) | <0.001 | |
| Heart failure | 338 (10.3) | 183 (8.6) | 155 (13.2) | <0.001 | |
| Previous myocardial infarction | 300 (9.1) | 172 (8.1) | 128 (10.9) | 0.01 | |
| Atrial fibrillation | 562 (17.1) | 346 (16.3) | 216 (18.3) | 0.16 | |
| Stroke | 316 (9.6) | 190 (9.0) | 126 (10.7) | 0.12 | |
| Peripheral artery disease | 136 (4.1) | 72 (3.4) | 64 (5.4) | 0.007 | |
| Hypertension | 1444 (43.8) | 770 (36.4) | 674 (57.2) | <0.001 | |
| Chronic obstructive pulmonary disease | 344 (10.4) | 207 (9.8) | 137 (11.6) | 0.11 | |
| Cancer | 646 (19.6) | 427 (20.2) | 219 (18.6) | 0.29 | |
| Liver disease | 128 (3.9) | 72 (3.4) | 56 (4.8) | 0.067 | |
| Rheumatic disease | 258 (7.8) | 163 (7.7) | 95 (8.1) | 0.76 | |
| Chronic renal disease | 385 (11.7) | 150 (7.1) | 235 (19.9) | <0.001 | |
| Lipidaemia | 470 (14.3) | 290 (13.7) | 180 (15.3) | 0.23 | |
| Concomitant pharmacotherapy, n (%) | |||||
| Antidiabetics | 951 (28.9) | 0 (0.0) | 951 (80.7) | <0.001 | |
| Insulin | 395 (12.0) | 0 (0.0) | 395 (33.5) | <0.001 | |
| Oral glucose‐lowering drugs | 801 (24.3) | 0 (0.0) | 801 (68.0) | <0.001 | |
| Cholesterol‐lowering drugs | 1344 (40.8) | 628 (29.7) | 716 (60.8) | <0.001 | |
| Beta‐blockers | 927 (28.1) | 494 (23.3) | 433 (36.8) | <0.001 | |
| Calcium channel blockers | 786 (23.9) | 440 (20.8) | 346 (29.4) | <0.001 | |
| Renin angiotensin system inhibitors | 1375 (41.7) | 738 (34.9) | 637 (54.1) | <0.001 | |
| Thiazides | 319 (9.7) | 204 (9.6) | 115 (9.8) | 0.96 | |
| Loop diuretics | 776 (23.6) | 393 (18.6) | 383 (32.5) | <0.001 | |
| Spironolactone | 181 (5.5) | 94 (4.4) | 87 (7.4) | <0.001 | |
| Digoxin | 144 (4.4) | 83 (3.9) | 61 (5.2) | 0.11 | |
| Aspirin | 542 (16.4) | 280 (13.2) | 262 (22.2) | <0.001 | |
| Adenosine diphosphate receptor inhibitors | 407 (12.4) | 245 (11.6) | 162 (13.8) | 0.077 | |
| Anticoagulants | 683 (20.7) | 407 (19.2) | 276 (23.4) | 0.005 |
Abbreviations: HbA1c, glycated haemoglobin; IQR, interquartile range.